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reimbursed for continued use of a therapy. Beneﬁt is evaluated
based on a priori criteria regarding what constitutes a clinically
important improvement. Payers incur costs for the patients
who meet established responder criteria for a given therapy.
METHODS: An economic evaluation of Sativex(r) vs. standard
analgesic care in adults with Multiple Sclerosis and neuropathic
pain is used to illustrate the application of a responder-based
reimbursement scenario (N = 66). Sativex(r) response was
deﬁned as a reduction in pain score (2-points on BS-11) on the
10th day of treatment based on clinician opinion. Base case
and responder-based incremental cost-utility ratios (ICUR) were
determined. Efﬁcacy and safety data were based on a phase III
pivotal trial. Costs (CND$ 2006) were based on provincial
sources. Direct medical resources were taken from a burden of
illness study. RESULTS: In the base case, the incremental cost
was $5339 and incremental QALY was 0.13. The ICUR was
$70,103/QALY. In the responder-based economic analysis,
55.9% of Sativex(r) patients were deﬁned as responders, incre-
mental costs was $9352 and incremental QALY was 0.21, result-
ing in an ICUR of $44,917/QALY. CONCLUSION: Progressive
licensing, in the form of conditional approvals, allows for earlier
market access to pharmaceutical products. Based on the condi-
tional nature of these approvals, the evidence for a new therapy
may not be deﬁnitive. However, their potential beneﬁt, by ﬁlling
a void for previously unmet medical need, is signiﬁcant. As
payers are interested in maximizing value for money, they may
not feel compelled to fund a conditionally-licensed product,
when the data supporting its value is considered uncertain. To
increase the conﬁdence in the value for money proposition,
responder-based reimbursement scenarios may be an option.
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OBJECTIVE: The PROLabels database (www.mapi-prolabels.
org) was developed to provide easy access to patient-reported
outcomes (PROs) included in approved labeling of products in
Europe and the USA. Two years after its launch, the coverage of
FDA labels has been extended to give a more comprehensive
image of the current use of PROs in clinical studies. METHODS:
In 2006, the database opened with drugs approved in Europe
through the centralized procedure established by the EMEA
in January 1995 and with New Molecular Entities (NME)
approved in the USA since January 1998. The extension project
focused on other chemical types approved by FDA (e.g. New
dosage form, New combination, etc.) and on NME approved
before 1998. Once a PRO claim was identiﬁed in a label, the drug
was added in PROLabels and the following information was
retrieved: the PRO claim, description of clinical studies support-
ing the claim, description of PRO endpoints and measures used,
pharmacological action of products and information source.
RESULTS: New ﬁgures resulting from this major extension of
PROLabels will be presented. These new ﬁgures will include the
number of drug products present in the database with the FDA/
EMEA distribution, the most represented therapeutic areas (cur-
rently nervous system diseases: 32.0%, immune system diseases:
24.0%, musculoskeletal diseases: 18.0%, genitourinary system
diseases: 14.8%, and respiratory system diseases: 13.2%), and
the most frequently measured PROs (currently Signs and Symp-
toms followed by Health-Related Quality of Life (HRQL)).
Finally, any change in the rate of PRO data found overall in FDA
approvals will be checked. CONCLUSION: This extension of
the FDA coverage of the PROLabels database allows a clearer
picture of the use of PROs to assess patients’ treatment beneﬁt to
be drawn. In addition, it facilitates the examination of the dis-
crepancies between the US and European regulatory agencies.
CANCER—Clinical Outcomes Studies
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OBJECTIVE: Protein HER2 identiﬁes a more aggressive subtype
of breast cancer. For this type of tumor, currently there are
speciﬁc treatments (trastuzumab and lapatinib), which, if used in
early phase of the disease can render a higher chance of cure and
survival to the patients (the HERA study showed that the use of
Herceptin after a standard chemotherapy in adjuvant tumors has
reduced by 46% the risk of a tumor to return). The study
objective is to assess the performance of the diagnostic tests
of this protein for Brazilian patients with breast cancer.
METHODS: A diary study with 220 Brazilian clinical oncolo-
gists was used; in the end of the study, a total of 3994 patients
with breast cancer were followed up. RESULTS: Fifty-eight
percent of the patients found were in the public market, and 42%
were from the private market. We also have that 64% of the
patients have early tumors (adjuvant or neoadjuvant), and 36%
have metastatic tumors. The HER2 test is performed in 80% of
the patients in the private market, with only 36% of the patients
of the public market being tested. The test performance rate
has little correlation with the disease phase (P value = 0.81);
however, there is some correlation of the performance of this test
with the patient’s age (P value = 0.3). Physicians from several
Brazilian states have different behavior while performing this
exam (P value = 6^162). CONCLUSION: We veriﬁed that few
patients of the public market (36%) perform this test comparing
with the private market (80%). We also veriﬁed great differences
in the performance of it in the different regions of the country. An
increased performance rate of this exam would increase the
chances of survival and cure for the patients, since it allows the
use of speciﬁc treatments for positive HER2 tumors.
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OBJECTIVE: The purpose of this study is to systematically
review the evidence of palonosetron in chemotherapy-induced
nausea and vomiting (CINV) and to understand its place in
therapy. METHODS: The English-language literature in OVID
and Cochrane databases were searched using the following
terms: palonosetron, antiemetics, CINV, and delayed. Of the 168
abstracts identiﬁed, 3 pivotal trials were deemed relevant by 2
independent reviewers. Guidelines from the American Society of
Clinical Oncology, National Comprehensive Cancer Network
(NCCN), and Multinational Association of Supportive Care in
Cancer and the Food and Drug Administration (FDA) reviewers’
comments on palonosetron were also obtained. RESULTS: The
trials, all non-inferiority studies, compared palonosetron
0.25mg to single-dose intravenous ondansetron or dolasetron.
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Two studies involved moderately emetogenic regimens. Pal-
onosetron 0.25mg was associated with a signiﬁcantly higher
complete response (CR) rate in the delayed phase compared to
ondansetron (74.1% vs. 55.1%, p = 0.001) and dolasetron
(54.0% vs. 38.7%, p = 0.004). The CR rate with palonosetron
0.25mg in the acute phase was signiﬁcantly higher than
ondansetron (81.0% vs. 68.6%, p = 0.009), but only numeri-
cally better than dolasetron (63.0% vs. 52.9%, p = 0.049). In
the trial with highly emetogenic agents, CR rates were compa-
rable between palonosetron 0.25 mg and ondansetron in both
the acute (59.2% vs. 57.0%, p = 0.701) and delayed (45.3%
vs. 38.9%, p = 0.180) phases. The FDA considered the CINV
claims relative to placebo due to lack of approval of compara-
tors for delayed CINV. Because of its long half-life, NCCN
guidelines indicated that single-dose palonosetron could be con-
sidered at the start of a multi-day chemotherapy regimen
instead of multiple daily doses of other 5-HT3-RAs; however,
none of the guidelines designated a preferred 5-HT3-RA. CON-
CLUSION: 5-HT3-RAs can be considered clinically inter-
changeable. While palonosetron may provide convenience by
avoiding the need for repeat daily dosing, this needs to be bal-
anced against its additional cost given the advent of generic
5-HT3-RAs.
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OBJECTIVE: Multiple myeloma (MM) is a plasma-cell malig-
nancy with approximately three years median survival. Patients
usually relapse or become refractory to existing treatments. Bort-
ezomib(VELCADE) is indicated for the treatment of MM in
patients who have received at least one prior therapy. The elec-
tronic VELCADE Observational Study (eVOBS) is a multicenter
naturalistic study designed to evaluate the clinical and outcomes
beneﬁts of bortezomib in actual clinical practice. METHODS:
This is a multi-center study with sites in Belgium, France, Greece,
Russia, Spain, Sweden, and Turkey. The study enrollment period
is between October 2006 and December 2008 with a 3-year
follow-up. Adults are eligible for study if they are scheduled to
initiate bortezomib within the approved indication. All bort-
ezomib dosages and concomitant treatments are permitted,
except investigational therapies. Data treatment response, and
safety are collected prospectively. RESULTS: The current analysis
reports data collected on patients initiated with bortezomib
between October 2006 and July 2007. A total of 86 pts with at
least four months of data are included in this analysis. Demo-
graphic and clinical characteristics of the initial participants were
similar to those of the participants in the prospective controlled
phase 3 APEX trial. Adverse events (AEs) were reported in 61
(71%) pts, including Grade 3 AEs in 38% and Grade 4 AEs
in 9%. AEs were treatment-related in 45% of patients and
treatment-limiting in 9%. Presently, 72 of 86 pts have been
evaluated for response, of whom 5 (7%) achieved complete
response, 9 (13%) achieved near complete response, and 30
(42%) achieved partial response. Updated data will be presented
at the meeting. CONCLUSION: In this preliminary analysis of
data from a prospective, observational study, response rates and
safety data demonstrate that bortezomib-containing regimens are
effective and well-tolerated in the treatment of MM in actual
clinical practice and the results are in line with previously pub-
lished studies.
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OBJECTIVES: The Nationwide Inpatient Sample is part of the
Healthcare Cost and Utilization Project, and is the only national
hospital database with charge information on all patients,
regardless of payer, including persons covered by Medicare,
Medicaid, private insurance, and the uninsured. It is the purpose
of this study to examine the relationship between patient out-
comes and conditions of the patients undergoing different treat-
ments for lung cancer. METHODS: There are ﬁfteen possible
patient diagnoses in the dataset. SAS Enterprise Guide was used
to obtain Lung Cancer data from NIS by using the CATX and the
RXMATCH statements in SAS. We bring all ﬁfteen diagnoses
into one column as a string of codes, using the CATX function.
Total charges are used to examine the relationship between diag-
noses and procedures. The generalized linear regression model
was used to ﬁt the data. RESULTS: After ﬁltering down to lung
cancer using the strings of diagnoses, there were 5457 records in
the data set. By the plot method, we selected variables related to
Total charges. We found that the Total charges were highly
related to Age in years at admission, Diagnosis Related Group,
Length of stay and Died during hospitalization. By the basic
criterion, deviance residuals and Pearson chi-square residuals,
the speciﬁed model ﬁts the data reasonably well. From the Type
1 and Type 3 analysis, all the estimates for the intercept, Los,
Age, DRG, and Died were 10.1805, 0.1181, 0.003, -0.0008, and
-1.024, respectively. All of them were statistically signiﬁcant.
Co-morbid diagnoses that increased total charges include coro-
naries, multiple signiﬁcant traumas, and cardiac implant. CON-
CLUSIONS: Our analysis revealed that there was a speciﬁed
relationship between these variables. With increasing of length of
stay, age in years at admission, small codes of diagnosis related
group and surviving during hospitalization, the total charges
increase, which is reasonable.
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OBJECTIVE: Complications from skeletal-related events (SREs)
constitute a challenge to the care of patients with bone metastasis
originated from any type of malignancy. Our objective was to
determine the reduction in morbidity (SREs) and mortality
(overall) of clodronate, pamidronate, and zoledronic acid in
patients diagnosed with bone metastasis. METHODS: Medline
and Embase (from inception to October 2007) were searched in
order to retrieve randomized clinical trials evaluating targeted
bisphosphonates in cancer patients with bone metastasis.
Patients with a deﬁnite (i.e., biopsy-proven) diagnosis of meta-
static bone disease were included in the analysis. We extracted
and combined data from studies describing the number of
patients reporting 12-month SREs and mortality data. Two inde-
pendent reviewers identiﬁed articles, then extracted data; results
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